Debbie Rigby takes a look at the latest in research
This review oers a description of PRN prescription and administration of psychotropic medications in aged care facilities. Variations were observed in the management of PRN psychotropic medications based on residents’ underlying health conditions and needs, duration of use, and changes between medications and doses. Neither the reasons for PRN prescription and administration nor the steps taken to identify and manage any associated adverse reactions or adverse drug events were reported.
This randomized, placebo-controlled study examined the effect of vitamin D replacement therapy on neuropathic symptoms and balance in patients with diabetic neuropathic pain and low vitamin D levels. Patients in the treatment group were intramuscularly (IM) injected with 300,000 IU vitamin D. The patients in the treatment group showed a significant decrease in symptoms of neuropathic pain and improved balance.
Journal of Pain Research 2020:13 171–179.
A large US population-based new-user cohort study has shown an association between SGLT@ inhibitors and the rate of gout compared to GLP1 agonists. The gout incidence rate was lower among patients prescribed an SGLT2 inhibitor (4.9 events per 1000 person-years) than those prescribed a GLP1 agonist (7.8 events per 1000 person-years), with an HR of 0.64.
Ann Intern Med. 2020.
Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo.
N Engl J Med 2019; 381:2497-2505.